Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery

References

• Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009; 5: 90–5
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Effect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugakku Zasshi 2006; 126: 1369–75
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J 2008; 10: 229–41
   PubMed Web of Science ®Google Scholar
• Araujo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine 2009; 5: 394–401
   PubMed Web of Science ®Google Scholar
• Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticles formulation using human cornea construct. Int J Pharm 2008; 355: 307–13
   PubMed Web of Science ®Google Scholar
• Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: Characterization. Eur J Pharm Biopharm 2007; 67: 48–57
   PubMed Web of Science ®Google Scholar
• Beck RCR, Pohlmann AR, Benvenutti EV, Costa DT, Guterres SS. Nanostructure-coated diclofenac-loaded microparticles: Preparation, morphological characterization, in vitro release and in vivo gastrointestinal tolerance. J Braz Chem Soc 2005; 16: 1233–40
   Web of Science ®Google Scholar
• Beckett AH, Stenlake JB. Practical pharmaceutical chemistry. Part 2: Physical methods of analysis4th. CBS Publishers, New Delhi 1997; 45–51
   Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions as ocular drug carriers. J Pharm Sci 1996; 85: 530–6
   PubMed Web of Science ®Google Scholar
• Costa P, Loba JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13: 123–33
   PubMed Web of Science ®Google Scholar
• Fessi HC, Devissaguet JP, Puisiex F, Thies C. 1992. Inventors, Centre National de la Recherche Scientifique, Paris, assignee. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US patent No. 5 118 528.
   Google Scholar
• Garcia-Cabanes C, Palmero M, Bellot JL, Orts A. PGE2 synthesis by corneal endothelial cells: Effect of glucocorticoids and NSAIDs. Ophthalmic Res 1999; 31: 42–6
   PubMedGoogle Scholar
• Gordon VJ, Araullo-Cruz T, Romanwoski EG. The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol 1998; 116: 900–5
   PubMedGoogle Scholar
• Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: Preparation, characterization and ocular anti-inflammatory studies. Int J Pharm 2000; 209: 1–14
   PubMed Web of Science ®Google Scholar
• Malhotra M, Majumdar DK. Permeation through cornea. Indian J Exp Biol 2001; 39: 11–24
   PubMedGoogle Scholar
• Malhotra M, Majumdar DK. Aqueous, oil and ointment formulations of ketorolac: Efficacy against prostaglandinE2-induced ocular inflammation and safety: A technical note. AAPS PharmSciTech, 2006;7:E1–6.
   Google Scholar
• Martin AN. Physical pharmacy: Physical chemical principles in the pharmaceutical sciences4th. Lippincott Williams and Wilkins, Philadelphia 1993
   Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2–3)165–96
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 2004; 56: 827–40
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002a; 16: 53–61
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen – loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002b; 23: 3247–55
   PubMed Web of Science ®Google Scholar
• Raizman M. Corticosteroid therapy of eye diseases; fifty years later. Arch Ophthalmol 1996; 114: 1000–1
   PubMed Web of Science ®Google Scholar
• Romanwoski EG, Gordon YJ. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model. Invest Ophthalmol Visual Sci 2001; 42: 158–62
   PubMedGoogle Scholar
• Schaffazick SR, Pohlmann AR, Dalla-costa D, Guterres SS. Freeze-drying polymeric colloidal suspensions: Nanocapsules, nanospheres and nanodispersion: A comparative study. Eur J Pharm Biopharm 2003; 56: 501–5
   PubMed Web of Science ®Google Scholar
• Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003; 217: 89–98
   PubMed Web of Science ®Google Scholar
• Schoenwald RD. Controlled drug bioavailability. Bioavailability control by drug delivery system design, VF Smolen, L Bull. John Wiley & Sons, New York 1985; 3: 257–306
   Google Scholar
• Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001; 48: 139–57
   PubMed Web of Science ®Google Scholar
• Sood R. Medical laboratory technology: Methods and interpretations4th. Jaypee Brothers, New Delhi 1999; 169–237
   Google Scholar
• Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Visual Sci 1980; 19: 1087–93
   PubMed Web of Science ®Google Scholar
• Sweetman CS. Martindale: The complete drug reference34th. Pharmaceutical Press, London 2005
   Google Scholar